Mode and site of action of therapies targeting CGRP signaling

The Journal of Headache and Pain

Review

Austeja Dapkute¹  Rami Burstein²  Nino Chkhitunidze³  Tamari Gudadze⁴  Cédric Gollion⁵  Hoda Naghshineh⁶  Edoardo Caronna⁷  Patricia Pozo-Rosich⁷  Liga Meksa⁸  Diana Braniste⁹  Alejandro Labastida-Ramírez^1,10  Jan Hoffmann^1,11  Emily Stanyer^1,12 

[1] Centre of Neurology, Vilnius University, Vilnius, Lithuania;Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA;Department of Anesthesia, Harvard Medical School, Boston, MA, USA;Center for Life Science, Room 649, 3 Blackfan Circle, 02215, Boston, MA, USA;Department of Neurology, Caucasus Medical Centre, Tbilisi, Georgia;Department of Neurology, Christian Hospital Unna, Unna, Germany;Department of Neurology, University Hospital of Toulouse, Toulouse, France;Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Science, Tehran, Iran;Headache Unit, Neurology Department, Vall d’Hebron Universitary Hospital, Barcelona, Spain;Headache Research Group, Vall d’Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain;Headache Unit, Neurology and Neurosurgery Department, Riga East University Hospital Gailezers, Riga, Latvia;Institute of Neurology and Neurosurgery, Diomid Gherman, Chișinău, Moldova;State University of Medicine and Pharmacy, Nicolae Testemițanu, Moldova;Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, SE1 1UL, London, UK;Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, SE1 1UL, London, UK;NIHR-Wellcome Trust King’s Clinical Research Facility/SLaM Biomedical Research Centre, King’s College Hospital, London, UK;Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, SE1 1UL, London, UK;Nuffield Department of Clinical Neurosciences, Sleep and Circadian Neuroscience Institute, University of Oxford, Oxford, UK;

关键词: Amylin;    Anti-CGRP;    Calcitonin;    Headache;    Migraine;    Trigeminal;   

DOI  :  10.1186/s10194-023-01644-8

 received in 2023-06-02, accepted in 2023-08-01,  发布年份 2023

来源: Springer

【 摘 要 】

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.

【 授权许可】

CC BY   
© Springer-Verlag Italia S.r.l., part of Springer Nature 2023

【 图 表 】

Fig. 1

13690_2023_1170_Article_IEq62.gif